Pfizer Inc (NYSE:PFE) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 59,856,772 shares, a growth of 14.0% from the April 30th total of 52,494,773 shares, StockRatingsNetwork.com reports. Currently, 0.9% of the shares of the company are sold short. Pfizer Inc. (NYSE:PFE) stock performance was -1.14% in last session and finished the day at $29.42. Traded volume was 26.82million shares in the last session and the average volume of the stock remained 30.38million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Analysts at Ladenburg Thalmann raised their price target on shares of Novavax Inc. (NASDAQ:NVAX) from $4.00 to $10.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, Novavax has an average rating of “Buy” and an average target price of $10.70. Novavax, Inc. (NASDAQ:NVAX) dropped -7.85 percent to $4.16 Friday on volume of 23.86million shares. The intra-day range of the stock was $4.09 to $4.26. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $871.63million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on June 3 announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on June 06, 2014 reported a decrease of -2.44% to the closing price of $6.00. Its fifty two weeks range is $4.05 -$9.05. The total market capitalization recorded $1.32billion. The overall volume in the last trading session was 10.55million shares. In its share capital, ARNA has 219.65million outstanding shares.

MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 133,000 shares of the company stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $9.95, for a total value of $1,323,350.00. Following the sale, the vice president now directly owns 102,286 shares of the company’s stock, valued at approximately $1,017,746.On Friday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 2.39% to close the day at $10.28. Company monthly performance is recorded as 65.81%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 80.04%.